FDA Drug recall D-0096-2017
Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50 mL Multiple-Dose Vial, Rx only, Hospira, Inc., Lake Forest, I…
- FDA Drug
- Class II
- terminated
- Published 2016-10-19
On 2016-10-19 the FDA classified a Class II recall of Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50 mL Multiple-Dose Vial, Rx only, Hospira, Inc., Lake Forest, I… by Hospira A Pfizer, citing lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be les….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0096-2017 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2016-09-16 |
| Published | 2016-10-19 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Hospira A Pfizer |
| Distribution | US |
Product
Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50 mL Multiple-Dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1587-50.
Reason
Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.
Identifiers
| ndc | 0409-1559-18 |
|---|---|
| ndc | 0409-1559-10 |
| ndc | 0409-1559-19 |
| ndc | 0409-1559-30 |
| ndc | 0409-1560-18 |
| ndc | 0409-1560-10 |
| ndc | 0409-1560-19 |
| ndc | 0409-1560-29 |
| ndc | 0409-1582-18 |
| ndc | 0409-1582-10 |
| ndc | 0409-1582-19 |
| ndc | 0409-1582-29 |
| ndc | 0409-1587-50 |
| ndc | 0409-1610-50 |
| ndc | 0409-1746-70 |
| ndc | 0409-1746-10 |
| ndc | 0409-1746-71 |
| ndc | 0409-1746-30 |
| ndc | 0409-1749-70 |
| ndc | 0409-1749-10 |
| ndc | 0409-1749-71 |
| ndc | 0409-1749-29 |
| ndc | 0409-1752-50 |
| ndc | 0409-1755-50 |
| ndc | 0409-2510-01 |
| ndc | 0409-2510-25 |
| ndc | 0409-7535-01 |
| ndc | 0409-7535-25 |
| ndc | 0409-1250-01 |
| ndc | 0409-1250-25 |
| ndc | 0409-5010-01 |
| ndc | 0409-5010-25 |
| ndc | 0409-1530-01 |
| ndc | 0409-1530-25 |
| ndc | 0409-0525-01 |
| ndc | 0409-0525-25 |
| ndc | 0409-7510-01 |
| ndc | 0409-7510-25 |
| ndc | 0409-2253-01 |
| ndc | 0409-2253-25 |
| code_info | Lot #: 60295DD, Ep 1DEC2017 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Other recalls by Hospira A Pfizer
- Labetalol Hydrochloride Injection, USP, 100 mg/ 20 mL (5 mg/mL), 20 mL Multidose Vial, Rx only, labeled as a) Hospira, Inc., Lake Forest, I…
FDA Drug · Class II · 2018-03-14 · Hospira A Pfizer - Neut Sodium Bicarbonate 4% (2.4 mEq) Additive Solution 5 mL , a.) Single-dose vial (NDC 0409-6609-02), b.) 25 vial carton (NDC 0409-6609-25…
FDA Drug · Class II · 2017-08-09 · Hospira A Pfizer - Potassium Phosphates Inj., USP, 45 mM (3 mM P/mL) Also contains: 66 mEq K+ (4.4 mEq/mL) 15 mL, Single-dose, Caution: Must Be Diluted, Rx On…
FDA Drug · Class II · 2017-08-09 · Hospira A Pfizer - 8.4% Sodium Bicarbonate Inj., USP 50 mL Single-dose, 50 mEq (1 mEq/mL) 4.2 grams (84 mg/mL), Rx Only, Mfd by Hospira, INC, Lake Forest, IL…
FDA Drug · Class II · 2017-08-09 · Hospira A Pfizer - Succinylcholine Chloride Injection, USP 200 mg (20 mg/mL) Quelicin Multiple-dose vial, 10 mL, For I.V. or I.M. use. a.) one vial (NDC: 0409…
FDA Drug · Class II · 2017-08-09 · Hospira A Pfizer
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0096-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.